Friday, 4 November 2011

FDA Approves U.S. Market Return for octagam® Following Octapharma's Implementation of Enhanced Safety Measures

HOBOKEN, N.J., Nov. 4, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) yesterday cleared the way for the U.S. market return of octagam® [Immune Globulin Intravenous (human) 5% Liquid Preparation], the Octapharma USA product used to treat disorders of the immune system. In August ...


Related News:-

  • FDA Upd8


  • Aubrey Inc., an advanced wound care company, announced it has received clearance from the US Food and Drug Administration (FDA) to market the AWBAT Plus product line in the ...
  • FDA Upd8


  • VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION), announced today that the U.S. Food and Drug Administration ("FDA") had responded to its Special Protocol Assessment ("SPA ...
  • Biotechnology Buzz


  • Regenicin, Inc. (OTC Bulletin Board: WDST) a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and ...
  • Health Upd8


  • The International Stroke Conference features more than 900 presentations on stroke science, and more than 3,500 attendees are expected. The American Stroke Association ...

No comments:

Post a Comment

Related Posts Plugin for WordPress, Blogger...